A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
This study has been completed.
Study NCT00000871
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999
Last Updated: December 19, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
